Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7099764 | 0.82 | NPC1 (1.00) | RAB9ANPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL7095984 | 0.81 | NPC1 (0.68) | RAB9ANPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL7095426 | 0.79 | NPC1 (0.75) | RAB9ANPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL7099332 | 0.78 | NPC1 (0.78) | RAB9ANPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL7101176 | 0.78 | NPC1 (0.76) | RAB9ANPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL7097002 | 0.78 | NPC1 (0.76) | RAB9ANPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL7099755 | 0.78 | NPC1 (0.76) | RAB9ANPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL7096050 | 0.77 | NPC1 (0.63) | RAB9ANPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL3643755 | 0.75 | RAB9A (0.60) | RAB9ANPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL7095985 | 0.75 | KMT2A (0.76) | RAB9ANPC1MAPTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-07-22 | — | — | US | disclosed |
| EP-0878196-B1 | KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6133258-A | PYRIDOTHIAZINE DERIVATIVE; FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, MULTIPLE SCLEROSIS, PAIN, GLAUCOMA | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| CN-1202109-A | Kainic acid neuronotoxicity inhibitors and pyridothioazine derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1998-12-16 | — | — | CN | disclosed |
| EP-0878196-A1 | KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | AHR, ARNT, ARSA | RAB9A 4056/4885NPC1 1022/4885MAPT 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.